These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 34013992

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
    Lipton RB, Goadsby PJ, Dodick DW, McGinley JS, Houts CR, Wirth RJ, Kymes S, Ettrup A, Østerberg O, Cady R, Ashina M, Buse DC.
    Headache; 2022 Jun; 62(6):690-699. PubMed ID: 35466430
    [Abstract] [Full Text] [Related]

  • 3. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
    Starling AJ, Cowan RP, Buse DC, Diener HC, Marmura MJ, Hirman J, Brevig T, Cady R.
    Headache; 2023 Feb; 63(2):264-274. PubMed ID: 36633219
    [Abstract] [Full Text] [Related]

  • 4. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
    McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R.
    J Headache Pain; 2022 Feb 07; 23(1):22. PubMed ID: 35130832
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R.
    Headache; 2021 Jan 07; 61(1):125-136. PubMed ID: 33314079
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
    Buse DC, Winner PK, Charleston L, Hirman J, Cady R, Brevig T.
    J Headache Pain; 2022 Feb 21; 23(1):29. PubMed ID: 35189811
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R.
    Headache; 2021 Oct 21; 61(9):1421-1431. PubMed ID: 34551130
    [Abstract] [Full Text] [Related]

  • 15. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
    Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S, Smith J, Schaeffler B.
    Clin Ther; 2020 Dec 21; 42(12):2254-2265.e3. PubMed ID: 33250209
    [Abstract] [Full Text] [Related]

  • 16. Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab.
    Jönsson L, Awad SF, Regnier SA, Talon B, Kymes S, Lee XY, Goadsby PJ.
    J Headache Pain; 2024 Mar 28; 25(1):45. PubMed ID: 38549121
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
    Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.
    Cephalalgia; 2019 Aug 28; 39(9):1075-1085. PubMed ID: 31234642
    [Abstract] [Full Text] [Related]

  • 19. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
    Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J.
    Cephalalgia; 2020 Mar 28; 40(3):241-254. PubMed ID: 32075406
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.